American Diabetes Association Diet Type 1

American Diabetes Association Diet Type 1

Position Statement

Diabetes and Hypertension: A Position Statement by the American Diabetes Association

1. Ian H. de Boer ¹,
2. Sripal Bangalore ²,
3. Athanase Benetos ³,
4. Andrew M. Davis ⁴,
5. Erin D. Michos ⁵,
6. Paul Muntner ⁶,
7. Peter Rossing ⁷,
8. Sophia Zoungas ⁸ and
9. George Bakris ⁴ ⇑

1. ¹University of Washington, Seattle, WA
2. ²New York University, New York, NY
3. ³Université de Lorraine, Nancy, France
4. ⁴The University of Chicago Medicine, Chicago, IL
5. ⁵The Johns Hopkins University School of Medicine, Baltimore, MD
6. ⁶School of Public Health, University of Alabama at Birmingham, Birmingham, AL
7. ⁷Steno Diabetes Center Copenhagen, University of Copenhagen, Copenhagen, Denmark
8. ⁸School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

1. Corresponding author: George Bakris, gbakris{at}medicine.bsd.uchicago.edu .

Introduction

Hypertension is common among patients with diabetes, with the prevalence depending on type and duration of diabetes, age, sex, race/ethnicity, BMI, history of glycemic control, and the presence of kidney disease, among other factors (1–3). Furthermore, hypertension is a strong risk factor for atherosclerotic cardiovascular disease (ASCVD), heart failure, and microvascular complications. ASCVD—defined as acute coronary syndrome, myocardial infarction (MI), angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin—is the leading cause of morbidity and mortality for individuals with diabetes and is the largest contributor to the direct and indirect costs of diabetes. Numerous studies have shown that antihypertensive therapy reduces ASCVD events, heart failure, and microvascular complications in people with diabetes (4–8). Large benefits are seen when multiple risk factors are addressed simultaneously (9). There is evidence that ASCVD morbidity and mortality have decreased for people with diabetes since 1990 (10,11) likely due in large part to improvements in blood pressure control (12–14). This Position Statement is intended to update the assessment and treatment of hypertension among people with diabetes, including advances in care since the American Diabetes Association (ADA) last published a Position Statement on this topic in 2003 (3).

DEFINITIONS, SCREENING, AND DIAGNOSIS

Recommendations

• Blood pressure should be measured at every routine clinical care visit. Patients found to have an elevated blood pressure (≥140/90 mmHg) should have blood pressure confirmed using multiple readings, including measurements on a separate day, to diagnose hypertension. B

• All hypertensive patients with diabetes should have home blood pressure monitored to identify white-coat hypertension. B

• Orthostatic measurement of blood pressure should be performed during initial evaluation of hypertension and periodically at follow-up, or when symptoms of orthostatic hypotension are present, and regularly if orthostatic hypotension has been diagnosed. E

Blood pressure should be measured at every routine clinical care visit (15). At the initial visit, blood pressure should be measured in both arms to detect and account for abnormalities that may lead to spurious blood pressures, such as arterial stenosis. Patients with elevated blood pressure (≥140/90 mmHg) who are not known to have hypertension should have elevated blood pressure confirmed on a separate day, within 1 month, to confirm the diagnosis of hypertension.

Office-based semiautomated oscillometric blood pressure (conventional or office blood pressure) is the conventional method used to diagnose hypertension and monitor treatment response. Blood pressure should be measured by a trained individual (15) in the seated position, with feet on the floor and arm supported at heart level. Cuff size should be appropriate for the upper-arm circumference (Table 1). To reduce within-patient variability, blood pressure should be measured after 5 min of rest, 2–3 readings should be taken 1–2 min apart, and blood pressure measurements should be averaged (16). It is particularly important to make and average repeated measurements of blood pressure for the diagnosis of hypertension and titration of antihypertensive treatment.

View this table:

• View inline

Table 1

Recommended blood pressure measurement cuff size for a given arm circumference

Automated office blood pressure (AOBP) is an alternate method to measure blood pressure in which a fully automated device is used to make and average multiple readings (usually 3–5) taken over a few minutes, ideally while a patient rests quietly alone (17). AOBP was used in two large, important clinical trials, Action to Control Cardiovascular Risk in Diabetes (ACCORD) (18) and Systolic Blood Pressure Intervention Trial (SPRINT) (19). If the patient is alone when the readings are taken, the approach is also useful for diagnosing white-coat hypertension (20). AOBP generates values 5–10 mmHg lower than conventional office readings, on average. Thus, results of trials using this technique cannot be directly applied to practices that measure conventional office blood pressure (17,21–23). With the exception of ACCORD (18), most of the evidence of benefits of hypertension treatment in people with diabetes is based on conventional office measurements.

Hypertension is defined as a sustained blood pressure ≥140/90 mmHg. This definition is based on unambiguous data that levels above this threshold are strongly associated with ASCVD, death, disability, and microvascular complications (1,2,24–27) and that antihypertensive treatment in populations with baseline blood pressure above this range reduces the risk of ASCVD events (4–6,28,29). The "sustained" aspect of the hypertension definition is important, as blood pressure has considerable normal variation. The criteria for diagnosing hypertension should be differentiated from blood pressure treatment targets.

Hypertension diagnosis and management can be complicated by two common conditions: masked hypertension and white-coat hypertension. Masked hypertension is defined as a normal blood pressure in the clinic or office (<140/90 mmHg) but an elevated home blood pressure of ≥135/85 mmHg (30); the lower home blood pressure threshold is based on outcome studies (31) demonstrating that lower home blood pressures correspond to higher office-based measurements. White-coat hypertension is elevated office blood pressure (≥140/90 mmHg) and normal (untreated) home blood pressure (<135/85 mmHg) (32). Identifying these conditions with home blood pressure monitoring can help prevent overtreatment of people with white-coat hypertension who are not at elevated risk of ASCVD and, in the case of masked hypertension, allow proper use of medications to reduce side effects during periods of normal pressure (33,34).

Home blood pressure measurements include daytime blood pressure measured with ambulatory blood pressure monitoring as well as measurements taken with home blood pressure monitors. The cuff size is very important, as too small a cuff will give higher than actual blood pressure values and too large a cuff will give values that are lower than actual blood pressure. The correct cuff size, such that the bladder encircles 80% of the arm (Table 1), should be used. The cuff should be placed such that the middle is on the patient's upper arm at the level of the right atrium (the midpoint of the sternum), and it should never be placed over clothes.

Orthostatic Hypotension

Diabetic autonomic neuropathy or volume depletion can cause orthostatic hypotension (35), which may be further exacerbated by antihypertensive medications. The definition of orthostatic hypotension is a decrease in systolic blood pressure of 20 mmHg or a decrease in diastolic blood pressure of 10 mmHg within 3 min of standing when compared with blood pressure from the sitting or supine position (36). Orthostatic hypotension is common in people with type 2 diabetes and hypertension and is associated with an increased risk of mortality and heart failure (37).

It is important to assess for symptoms of orthostatic hypotension to individualize blood pressure goals, select the most appropriate antihypertensive agents, and minimize adverse effects of antihypertensive therapy. Additionally, antihypertensive medication type or timing (switch to nocturnal dosing) may require adjustment. In particular, α-blockers and diuretics may need to be stopped. People with orthostatic hypotension may benefit from support stockings or other approaches (38).

BLOOD PRESSURE TARGETS

Recommendations

• Most patients with diabetes and hypertension should be treated to a systolic blood pressure goal of <140 mmHg and a diastolic blood pressure goal of <90 mmHg. A

• Lower systolic and diastolic blood pressure targets, such as <130/80 mmHg, may be appropriate for individuals at high risk of cardiovascular disease if they can be achieved without undue treatment burden. B

Epidemiologic analyses show that blood pressure ≥115/75 mmHg is associated with increased rates of ASCVD (27), heart failure, retinopathy, kidney disease, and mortality in a graded fashion, contributing to the evidence that blood pressure control is important in the clinical outcomes of diabetes (1,2,24,26,39). However, observational studies of blood pressure targets are subject to confounding factors and do not directly assess the effects of blood pressure lowering. Clinical trials and meta-analyses of clinical trials provide the strongest evidence addressing blood pressure and offer substantial guidance for treatment targets, particularly for patients with type 2 diabetes.

Treatment of hypertension to blood pressure <140/90 mmHg is supported by unequivocal evidence that pharmacologic treatment of blood pressure ≥140/90 mmHg reduces cardiovascular events as well as some microvascular complications. In type 2 diabetes, the UK Prospective Diabetes Study (UKPDS) showed that targeting blood pressure <150/85 mmHg versus <180/105 mmHg reduced composite microvascular and macrovascular diabetes complications by 24% (28). Moreover, meta-analyses of clinical trials demonstrate that antihypertensive treatment of populations with diabetes and baseline blood pressure ≥140/90 mmHg reduces the risks of ASCVD, heart failure, retinopathy, and albuminuria (4–8,40). Therefore, most patients with type 1 or type 2 diabetes who have hypertension should, at a minimum, be treated to blood pressure targets of <140/90 mmHg.

Intensification of antihypertensive therapy to target blood pressures lower than <140/90 mmHg (e.g., <130/80 or <120/80 mmHg) may be beneficial for selected patients with diabetes. Such intensive blood pressure control has been evaluated in landmark clinical trials and meta-analyses of clinical trials.

Randomized Clinical Trials of Intensive Blood Pressure Control

The ACCORD blood pressure (ACCORD BP) trial examined the effects of intensive blood pressure control (goal systolic blood pressure <120 mmHg) versus standard blood pressure control (target systolic blood pressure <140 mmHg) among people with type 2 diabetes. Additional studies, such as Hypertension Optimal Treatment (HOT) trial and SPRINT, also examined the potential benefits of intensive versus standard blood pressure control, though the relevance of their results to people with diabetes is less clear. The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation–Blood Pressure (ADVANCE BP) trial, which tested the effects of a fixed-dose combination of antihypertensive interventions versus placebo among people with type 2 diabetes, also informs blood pressure targets (41). Study details are given in Table 2.

View this table:

• View inline

Table 2

Randomized controlled trials of intensive vs. standard hypertension treatment strategies

In ACCORD BP, intensive blood pressure control did not reduce total major atherosclerotic cardiovascular events but did reduce the risk of stroke, at the expense of increased adverse events (18). Specifically, compared with a target systolic blood pressure <140 mmHg, a target systolic blood pressure <120 mmHg resulted in no significant difference in the primary composite outcome of MI, stroke, or cardiovascular death (hazard ratio 0.88, 95% CI 0.73 to 1.06). Stroke was reduced by 41% (hazard ratio 0.59, 95% CI 0.39 to 0.89), but serious adverse events attributed to antihypertensive therapy occurred in 3.3% vs. 1.3% of participants, with significantly increased incidence of hypotension, electrolyte abnormalities, and elevated serum creatinine. Therefore, the ACCORD BP results suggest that blood pressure targets more intensive than <140/90 mmHg may be reasonable in selected patients who have been educated about added treatment burden, side effects, and costs (18,42). The achieved blood pressure in ADVANCE in the intervention group (136/73) was higher than that achieved in ACCORD intensive arm (119/64 mmHg) and would be consistent with a target blood pressure of <140/90 mmHg, though ADVANCE did not explicitly test blood pressure targets (43). Of note, ACCORD BP and SPRINT measured blood pressure using AOBP, which yields values that are generally lower than typical office blood pressure by approximately 5–10 mmHg (17), suggesting that implementing the ACCORD BP or SPRINT protocols in a typical clinic might require a systolic blood pressure target higher than <120 mmHg.

Meta-analyses of Trials

Meta-analyses of placebo-controlled clinical trials using multiple classes of antihypertensive medications clearly demonstrate that antihypertensive treatment in general reduces the risks of ASCVD, heart failure, retinopathy, albuminuria, and mortality among people with diabetes (4–8,40). Overall, compared with people without diabetes, the relative benefits of antihypertensive treatment are similar, and absolute benefits may be greater (5,8,40). To clarify optimal blood pressure targets in the setting of diabetes, meta-analyses have stratified clinical trials by mean baseline blood pressure or mean blood pressure attained in the intervention or intensive treatment arm. Based on these analyses, antihypertensive treatment appears to be beneficial when mean baseline blood pressure is ≥140/90 mmHg or mean attained intensive blood pressure is ≥130/80 mmHg (4,6–8). Among trials with lower baseline or achieved blood pressure, antihypertensive treatment reduced the risk of stroke, retinopathy, and albuminuria, but effects on other ASCVD and heart failure were not evident. A critical point is that these are all trial-level meta-analyses that are subject to confounding and imprecise in their stratification, as opposed to individual-level meta-analyses, which are needed to best address the issue (8). In addition, meta-analyses have focused largely on treatment benefits, and additional data weighing potential harms are needed. Taken together, these meta-analyses consistently show that treating patients with baseline blood pressure ≥140 mmHg to targets <140 mmHg is beneficial, while more intensive targets may offer additional though probably less robust benefits.

Individualization of Treatment Targets

Patients and clinicians should engage in a shared decision-making process to determine individual blood pressure targets, with the acknowledgment that the benefits and risks of intensive blood pressure targets are uncertain and may vary across patients. Following the ADA approach to the management of hyperglycemia, factors that influence treatment targets may include risks of treatment (e.g., hypotension, drug adverse effects), life expectancy, comorbidities including vascular complications, patient attitude and expected treatment efforts, and resources and support system (44). Specific factors to consider are the absolute risk of cardiovascular events (40,45), risk of progressive kidney disease as reflected by albuminuria, adverse effects, age, and overall treatment burden. Patients who have higher risk of cardiovascular events (particularly stroke) or albuminuria and who can attain intensive blood pressure control relatively easily and without substantial adverse effects may be best suited to intensive blood pressure control. In contrast, patients with conditions more common in older adults, such as functional limitations, polypharmacy, and multimorbidity, may be best suited to less intensive blood pressure control.

Notably, there is an absence of high-quality data available to guide blood pressure targets in type 1 diabetes. Associations of blood pressure with macrovascular and microvascular outcomes in type 1 diabetes are generally similar to those in type 2 diabetes and the general population (1). Given an absence of randomized trials with clinical outcomes in type 1 diabetes, effects of antihypertensive therapy can only be extrapolated from trials in other populations, potentially drawing from both ACCORD BP and SPRINT. Of note, diastolic blood pressure, as opposed to systolic blood pressure, is a key variable predicting cardiovascular outcomes in people under age 50 years without diabetes and may be prioritized in younger adults (46,47). Though convincing data are lacking, younger adults with type 1 diabetes might more easily achieve intensive blood pressure levels and may derive substantial long-term benefit from tight blood pressure control.

TREATMENT

Lifestyle Management

Recommendation

• For patients with systolic blood pressure >120 mmHg or diastolic blood pressure >80 mmHg, lifestyle intervention consists of weight loss if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reduced sodium and increased potassium intake; increased fruit and vegetable consumption; moderation of alcohol intake; and increased physical activity. B

Lifestyle management is an important component of hypertension treatment because it lowers blood pressure, enhances the effectiveness of some antihypertensive medications, promotes other aspects of metabolic and vascular health, and generally leads to few adverse effects. In addition, patients with diabetes and systolic blood pressure >120 mmHg or diastolic blood pressure >80 mmHg are at risk for developing hypertension and its complications (48,49), and lifestyle management may help prevent or delay a diagnosis of hypertension with need for pharmacologic therapy. To facilitate long-term maintenance of behavioral change, lifestyle therapy should be adapted to suit the needs of the patient and discussed as part of diabetes management.

Although there are no well-controlled studies of diet and exercise in the treatment of elevated blood pressure or hypertension in individuals with diabetes, the Dietary Approaches to Stop Hypertension (DASH) study evaluated the impact of healthy dietary patterns in individuals without diabetes and has shown antihypertensive effects similar to those of pharmacologic monotherapy (50). A recent meta-analysis found that lifestyle intervention can help lower blood pressure in patients with type 2 diabetes (51). Medium- or high-intensity combined lifestyle counseling has shown benefit in patients selected for cardiovascular risk factors, including diabetes, for the intermediate outcomes of blood pressure, lipids, fasting blood glucose, and weight, especially over 12 to 24 months (52).

Lifestyle therapy consists of reducing excess body weight through caloric restriction, restricting sodium intake (<2,300 mg/day), increasing consumption of fruits and vegetables (8–10 servings per day) and low-fat dairy products (2–3 servings per day), avoiding excessive alcohol consumption (no more than 2 servings per day in men and no more than 1 serving per day in women) (53), smoking cessation, reducing sedentary time (54), and increasing physical activity levels (55). These lifestyle strategies may also positively affect glycemic and lipid control and should be encouraged in those with even mildly elevated blood pressure. In addition, clinicians are encouraged to routinely review patient medication lists for agents that may raise blood pressure, including over-the-counter and herbal ones. As an example, one meta-analysis suggested that nonsteroidal anti-inflammatory drugs increase systolic blood pressure on average by 5 mmHg (56).

Sodium

Sodium reduction has not been tested in controlled clinical trials in people with diabetes. However, results from trials in primary hypertension have shown a reduction in systolic blood pressure of ∼5 mmHg and diastolic blood pressure of 2–3 mmHg with moderate sodium reduction (from a daily intake of 200 mmol [4,600 mg] to 100 mmol [2,300 mg] of sodium per day) (57). A dose-response effect has been observed with sodium reduction. Even when pharmacologic agents are used, there may be a better response when there is concomitant salt restriction due to the volume component of hypertension.

Physical Activity

Moderately intense physical activity, such as 30–45 min of brisk walking most days of the week, has been shown to lower blood pressure (58). Regular exercise may lower blood pressure, necessitating dose adjustment of antihypertension medications (59). β-Blockers may reduce maximal exercise capacity, while diuretics may increase risk of dehydration. Physical activities should be promoted in all patients including older adults with physical limitations. The type and intensity of physical activities should be adapted to the preferences and functional status of the patient.

Weight Loss

Weight reduction should be considered in the management of blood pressure. The loss of 1 kg in body weight has been associated with a decrease in blood pressure of ∼1 mmHg (60). Some weight-loss medications may induce increases in blood pressure levels, so these must be used with care.

Sleep Apnea

Treatment of obstructive sleep apnea has been shown to reduce blood pressure in randomized studies of people with diabetes (61).

Pharmacologic Antihypertensive Treatment

Recommendations

• Patients with confirmed office-based blood pressure ≥140/90 mmHg should, in addition to lifestyle therapy, have timely titration of pharmacologic therapy to achieve blood pressure goals. A

• Patients with confirmed office-based blood pressure ≥160/100 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely titration of two drugs or a single-pill combination of drugs demonstrated to reduce cardiovascular events in patients with diabetes. A

• Treatment for hypertension should include drug classes demonstrated to reduce cardiovascular events in patients with diabetes: ACE inhibitors, angiotensin receptor blockers (ARBs), thiazide-like diuretics, or dihydropyridine calcium channel blockers. Multiple-drug therapy is generally required to achieve blood pressure targets (but not a combination of ACE inhibitors and ARBs). A

• An ACE inhibitor or ARB, at the maximum tolerated dose indicated for blood pressure treatment, is the recommended first-line treatment for hypertension in patients with diabetes and urine albumin-to-creatinine ratio ≥300 mg/g creatinine (A) or 30–299 mg/g creatinine (B). If one class is not tolerated, the other should be substituted. B

• For patients treated with an ACE inhibitor, ARB, or diuretic, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. B

Initial Number of Antihypertensive Medications

Initial treatment for people with diabetes depends on the severity of hypertension (Fig. 1). Those with blood pressure between 140/90 mmHg and 159/99 mmHg may begin with a single drug. For patients with blood pressure ≥160/100 mmHg, initial pharmacologic treatment with two antihypertensive medications is recommended. The Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) trial was one of the first trials to evaluate whether a higher percentage of people with diabetes would achieve the blood pressure goal when a single-pill combination was given rather than monotherapy at average blood pressures above 160/100 mmHg. The 214 patients received initial therapy with an ACE inhibitor plus dihydropyridine calcium channel blocker (CCB) compared with the ACE inhibitor alone, which resulted in an increased proportion of participants achieving the target blood pressure at 3 months (63% vs. 37%; P = 0.002) (62). The Simplified Treatment Intervention to Control Hypertension (STITCH) trial randomized over 2,000 patients with and without diabetes whose mean blood pressure was ∼160/95 mmHg to an ACE inhibitor alone or ACE inhibitor plus thiazide-like diuretic and found that the proportion of patients achieving a blood pressure <140/90 mmHg at 6 months was higher in the combination intervention group (65% vs. 53%; P = 0.026) (63). Single-pill combinations may improve medication adherence (64).

• Download figure
• Open in new tab
• Download powerpoint

Figure 1

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension for patients with UACR 30–299 mg/g creatinine and strongly recommended for patients with UACR ≥300 mg/g creatinine. **Thiazide-like diuretic; long-acting agents shown to reduce cardiovascular events, such as chlorthalidone and indapamide, are preferred. ***Dihydropyridine. BP, blood pressure.

Classes of Antihypertensive Medications

Initial treatment for hypertension should include drug classes demonstrated to reduce cardiovascular events in patients with diabetes: ACE inhibitors (65,66), angiotensin receptor blockers (ARBs) (65,66), thiazide-like diuretics (67), or dihydropyridine CCBs (68). For patients with albuminuria (urine albumin-to-creatinine ratio [UACR] ≥30 mg/g creatinine), initial treatment should include an ACE inhibitor or ARB in order to reduce the risk of progressive kidney disease, detailed below. In the absence of albuminuria, risk of progressive kidney disease is low, and ACE inhibitors and ARBs have not been found to afford superior cardioprotection when compared with other antihypertensive agents (69). β-Blockers may be used for the treatment of coronary disease or heart failure but have not been shown to reduce mortality as blood pressure–lowering agents in the absence of these conditions (5,70).

Multiple-Drug Therapy

Multiple-drug therapy is often required to achieve blood pressure targets, particularly in the setting of diabetic kidney disease. However, the use of both ACE inhibitors and ARBs in combination is not recommended given the lack of added ASCVD benefit and increased rate of adverse events—namely, hyperkalemia, syncope, and acute kidney injury (71–73). Titration of and/or addition of further blood pressure medications should be made in a timely fashion to overcome clinical inertia in achieving blood pressure targets.

There is only one large trial including people with diabetes that randomized two single-pill combinations and assessed cardiovascular and renal outcomes. The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial enrolled participants at high risk of cardiovascular events (60% with diabetes) and demonstrated a decrease in morbidity and mortality with the ACE inhibitor benazepril plus the dihydropyridine CCB amlodipine versus benazepril and the thiazide-like diuretic hydrochlorothiazide (68,74). Other such trials are needed to confirm these outcomes and assess other antihypertensive medication combinations.

Diabetic Kidney Disease

Patients with diabetes and albuminuria (UACR ≥30 mg/g creatinine and particularly ≥300 mg/g creatinine) are at increased risk of progressive kidney disease (24). In this setting, ACE inhibitors and ARBs have unique renoprotective advantages in the treatment of hypertension. Outcome trials of people with type 1 and type 2 diabetes and established diabetic kidney disease (including urinary albumin excretion ≥300 mg/g creatinine) have demonstrated that an ACE inhibitor or ARB, at a maximal antihypertensive dose, slows the progression of kidney disease compared with placebo (75–77). Therefore, patients with urinary albumin excretion ≥300 mg/g creatinine should have an ACE inhibitor or an ARB included as part of their blood pressure–lowering regimen. Clinicians should also consider an ACE inhibitor or ARB in patients with hypertension at any level of albuminuria (urinary albumin excretion ≥30 mg/g creatinine) (66).

In the absence of albuminuria, the superiority of ACE inhibitors or ARBs over other antihypertensive agents for prevention of cardiovascular outcomes has not been consistently shown (66,69,78,79), although smaller trials suggest reduction in composite cardiovascular events and reduced progression to advanced stages of kidney disease (80–82). In general, ACE inhibitors and ARBs are considered to have similar benefits and risks, and if one is not tolerated, the other can often be used (65,83).

Hyperkalemia and Acute Kidney Injury

In people with diabetic kidney disease, hyperkalemia risk dramatically increases when the estimated glomerular filtration rate (eGFR) is below 45 mL/min/1.73 m² or serum potassium is >4.5 mEq/L while the patient is already receiving a diuretic (84). Moreover, the combination of reduced eGFR and elevated potassium in a given patient can raise the risk eightfold for hyperkalemia development if spironolactone and an ACE inhibitor or ARB are added (85).

Thiazide-like diuretics are only effective in maintaining volume and reducing the risk of hyperkalemia down to an eGFR of 30 mL/min/1.73 m² (86,87). Below an eGFR of 30 mL/min/1.73 m², a long-acting loop diuretic, such as torsemide, should be prescribed instead.

To prevent inadvertent declines in eGFR, patients treated with an ACE inhibitor or ARB should be aware of volume status and avoid volume depletion to reduce the risk for acute kidney injury. Also, in volume depleted states, risk for hyperkalemia increases (71,72,88).

Bedtime Dosing

Evidence suggests an association between absence of nocturnal blood pressure dipping and ASCVD events. A meta-analysis of clinical trials found a small benefit of evening versus morning dosing of antihypertensive medications with regard to blood pressure control but no data on clinical effects (89). In two subgroup analyses of a single subsequent randomized clinical trial, moving at least one antihypertensive medication to bedtime significantly reduced cardiovascular events, but results were based on small numbers of events (90,91).

Monitoring

Recommendation

• In patients receiving pharmacologic antihypertensive treatment, home blood pressure should be measured to promote patient engagement in treatment and adherence. B

Self-management is a key component of diabetes care and extends to antihypertensive treatment. Home blood pressures may improve patient medication adherence (92–94) and reduce cardiovascular risk factors (95). Furthermore, evidence suggests home blood pressure monitoring is as accurate as 24-h ambulatory blood pressure monitoring (96,97) and may better correlate with ASCVD risk than office measurements (98,99).

Interactions with Diabetes Medications

Hyperinsulinemia and exogenous insulin may theoretically lead to hypertension through vasoconstriction and sodium and fluid retention (100). However, insulin can also promote vasodilation, and basal insulin compared with standard care was not associated with a change in blood pressure in the Outcome Reduction With an Initial Glargine Intervention (ORIGIN) trial of people with type 2 diabetes or prediabetes (101).

Sodium–glucose cotransport 2 inhibitors are associated with a mild diuretic effect and a reduction in blood pressure of 3–6 mmHg systolic blood pressure and 1–2 mmHg diastolic blood pressure (102,103). Glucagon-like peptide 1 receptor agonists are also associated with a reduction in systolic/diastolic blood pressure of 2–3/0–1 mmHg (104).

RESISTANT HYPERTENSION

Recommendations

• Patients with resistant hypertension who are not meeting blood pressure targets on conventional drug therapy with three agents, including a diuretic, should be referred to a certified hypertension specialist. E

• Patients with resistant hypertension who are not meeting blood pressure targets on conventional drug therapy with three agents should be considered for mineralocorticoid receptor antagonist therapy. B

Resistant hypertension is defined as blood pressure ≥140/90 mmHg despite a therapeutic strategy that includes appropriate lifestyle management plus a diuretic and two other antihypertensive drugs belonging to different classes at adequate doses. Prior to diagnosing resistant hypertension, several other conditions should be excluded (Table 3).

View this table:

• View inline

Table 3

Conditions to exclude before making the diagnosis of resistant hypertension

Since multiple agents are often necessary to achieve blood pressure targets, medication adherence issues may present as resistant hypertension. Potential barriers to medication adherence (such as cost, number of medications, and side effects) should routinely be assessed. If blood pressure remains uncontrolled despite confirmed adherence, clinicians should consider an evaluation for secondary causes of hypertension.

Mineralocorticoid receptor antagonists (MRAs) are effective for management of resistant hypertension in patients with type 2 diabetes when added to existing treatment with a renin-angiotensin system (RAS) inhibitor, diuretic, and CCB (105), in part because they reduce sympathetic nerve activity (106). MRAs also reduce albuminuria and have additional cardiovascular benefits (107–110). However, adding an MRA to an ACE inhibitor or ARB may increase the risk for hyperkalemic episodes. Hyperkalemia can be managed with dietary potassium restriction, potassium-wasting diuretics, or potassium binders (111), but long-term outcome studies are needed to evaluate the role of MRAs (with or without adjunct potassium management) in blood pressure management.

PREGNANCY

Recommendations

• Pregnant women with diabetes and preexisting hypertension or mild gestational hypertension with systolic blood pressure <160 mmHg, diastolic blood pressure <105 mmHg, and no evidence of end-organ damage do not need to be treated with pharmacologic antihypertensive therapy. E

• In pregnant patients with diabetes and preexisting hypertension who are treated with antihypertensive therapy, systolic or diastolic blood pressure targets of 120–160/80–105 mmHg are suggested in the interest of optimizing long-term maternal health and fetal growth. E

The American College of Obstetricians and Gynecologists (ACOG) does not recommend that women with mild gestational hypertension (systolic blood pressure <160 mmHg or diastolic blood pressure <110 mmHg) be treated with antihypertensive medications, as there is no benefit identified that clearly outweighs potential risks of therapy (112). A Cochrane systematic review did not find conclusive evidence for or against blood pressure treatment for mild to moderate preexisting hypertension to reduce the risk of preeclampsia, preterm birth, small-for-gestational-age infants, or fetal death (113). For pregnant women at high risk of preeclampsia, low-dose aspirin is recommended starting at 12 weeks of gestation to reduce the risk of preeclampsia (114).

For women requiring antihypertensive therapy, blood pressure should be maintained between 120 and 160 mmHg systolic and 80 and 105 mmHg diastolic, as lower blood pressure levels may be associated with impaired fetal growth. Pregnant women with hypertension and evidence of end-organ damage including cardiovascular and renal diseases may be considered for lower blood pressure targets (i.e., <140/90 mmHg) to avoid the progression of these diseases during pregnancy.

During pregnancy, treatment with ACE inhibitors, ARBs, or spironolactone is contraindicated, as they may cause fetal damage. Antihypertensive drugs known to be effective and safe in pregnancy include methyldopa, labetalol, hydralazine, and long-acting nifedipine. Diuretics may be used during late-stage pregnancy if needed for volume control (115). Postpartum patients with gestational hypertension, preeclampsia, and superimposed preeclampsia should have their blood pressures observed for 72 h in the hospital and for 7–10 days' postpartum (112). Long-term follow-up is recommended for these women, as they have increased lifetime cardiovascular risk.

OLDER ADULTS (Aged ≥65 Years)

Arterial stiffness may develop during the aging process and contribute to an increase in systolic and decrease in diastolic blood pressure in older adults (116,117). Diabetes is itself associated with an increase in arterial stiffness (118), leading to a greater age-related increase in systolic blood pressure compared with people without diabetes (119–121). Older adults with diabetes and hypertension (mainly systolic) typically present with high risk for cardiovascular events and other age-related diseases (122–124), difficulties achieving blood pressure targets due to arterial stiffness, and high risk of iatrogenic complications, including hypoglycemia, orthostatic hypotension, and volume depletion.

In older adults with diabetes and hypertension, functional status, comorbidities, and polypharmacy are important considerations when establishing therapeutic strategies and blood pressure goals (125). Systolic blood pressure should be the main target of treatment. In fitter patients, a therapeutic strategy similar to that used in younger individuals may be used. In the subgroup with loss of autonomy and major functional limitations (e.g., those needing daily assistance for their basic activities), higher systolic blood pressure goals should be considered (e.g., 145–160 mmHg) and treatment should be reduced in the presence of low supine systolic blood pressure (<130 mmHg) or presence of orthostatic hypotension (125,126).

In older people with impaired vascular compliance, as indicated by a difference of >60 mmHg between systolic and diastolic pressures (i.e., pulse pressure), attempts to reach a target systolic pressure must be balanced against the risk of lowering diastolic pressure below 65–70 mmHg. Lowering diastolic pressures below this range in older adults may increase the risk for coronary heart disease, mortality, and other adverse cardiovascular outcomes (127–130).

When considering pharmacologic antihypertensive treatment in older adults with diabetes, note that β-blockers may mask signs of hypoglycemia, antihypertensive drugs can worsen orthostatic hypotension, and diuretics can exacerbate volume depletion. Cognitive dysfunction may affect medication-taking behaviors, particularly in the context of poor overall health status, multiple comorbidities, acute illness, polypharmacy, and poor nutrition. Tolerance of the antihypertensive treatment should be regularly assessed, especially orthostatic hypotension.

ANTIHYPERTENSIVE TREATMENT IN THE ABSENCE OF HYPERTENSION

For people with diabetes and untreated blood pressure <140/90 mmHg, there is little evidence that antihypertensive treatment improves health outcomes. Some have suggested treatment with an ACE inhibitor or ARB to prevent or delay diabetic kidney disease, but the data do not support such an approach. In a trial of people with type 2 diabetes and normal urine albumin excretion with and without hypertension, an ARB reduced or suppressed the development of albuminuria but increased the rate of cardiovascular events (131). In two trials of patients without albuminuria or hypertension, one including people with type 1 diabetes (132) and the other type 2 diabetes (133), RAS inhibitors did not prevent the development of diabetic glomerulopathy assessed by kidney biopsy. Therefore, RAS inhibitors are not recommended for patients without hypertension to prevent the development of diabetic kidney disease.

CONCLUSIONS

Hypertension is a strong, modifiable risk factor for the macrovascular and microvascular complications of diabetes. Robust literature demonstrates the clinical efficacy of lowering blood pressure, with cardiovascular and microvascular benefits demonstrated for multiple classes of antihypertensive medications. Strong evidence from clinical trials and meta-analyses supports targeting blood pressure reduction to at least <140/90 mmHg in most adults with diabetes. Lower blood pressure targets may be beneficial for selected patients with high cardiovascular disease risk if they can be achieved without undue burden, and such lower targets may be considered on an individual basis. In addition to lifestyle modifications, multiple medication classes are often needed to attain blood pressure goals. ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide-like diuretics have been demonstrated to improve clinical outcomes and are preferred for blood pressure control. For patients with albuminuria, an ACE inhibitor or ARB should be part of the antihypertensive regimen. Treatment should be individualized to the specific patient based on their comorbidities; their anticipated benefit for reduction in ASCVD, heart failure, progressive diabetic kidney disease, and retinopathy events; and their risk of adverse events. This conversation should be part of a shared decision-making process between the clinician and the individual patient.

Article Information

Acknowledgments. We would very much like to express our gratitude and thanks to Erika Gebel Berg of the ADA for her help in writing the manuscript drafts and coalescing information from all the authors.

Funding and Duality of Interest. I.H.d.B. has been a consultant for Boehringer Ingelheim and Ironwood Pharmaceuticals, and his institution has received research equipment and supplies from Medtronic and Abbott. S.B. has received research grants from the National Heart, Lung, and Blood Institute and Abbott Vascular; has been on advisory boards for Pfizer, AstraZeneca, and The Medicines Company; and has received speaker fees from Merck, Abbott, Pfizer, and Abbott Vascular. A.B. has received honoraria from Fukuda-Denshi. E.D.M. has received an honorarium from Siemens Healthcare Diagnostics for being a blinded events adjudicator in a clinical trial unrelated to the subject of this article (i.e., it was not related to either hypertension or diabetes). P.M. has received research support and honorarium from Amgen. P.R. has been a steering committee member for A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) (AstraZeneca) and Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO)/Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO) (Bayer) and has received consultancy and/or speaking fees (all honoraria to his institution) from AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. S.Z. has been a consultant for AstraZeneca/Bristol-Myers Squibb Australia, Janssen-Cilag, Merck Sharp & Dohme, Novo Nordisk, Sanofi Australia, and Servier International. G.B. has been a principal investigator on FIDELIO (Bayer), a steering committee member for Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) (Janssen) and Study Of Diabetic Nephropathy With Atrasentan (SONAR) (AbbVie), and a consultant for Merck, Relypsa, Vascular Dynamics, GlaxoSmithKline, Bayer, Janssen, and AbbVie. No other potential conflicts of interest relevant to this article were reported.

Footnotes

• This position statement was reviewed and approved by the American Diabetes Association Professional Practice Committee in June 2017 and ratified by the American Diabetes Association Board of Directors in July 2017.

• For further information on the ADA evidence grading system and the levels of evidence, please see Table 1 in the American Diabetes Association's Introduction section of the Standards of Medical Care in Diabetes—2017. Diabetes Care 2017;40(Suppl. 1):S2, https://doi.org/10.2337/dc17-S001.

• This article is featured in a podcast available at http://www.diabetesjournals.org/content/diabetes-core-update-podcasts.

• © 2017 by the American Diabetes Association.

American Diabetes Association Diet Type 1

Source: https://care.diabetesjournals.org/content/40/9/1273

Read More

Webiste To Mockup Playing Cards

Webiste To Mockup Playing Cards

How to Get a Credit Card

Photo Courtesy: 10'000 Hours/DigitalVision/Getty Images

Getting a credit card is a fairly straightforward process that requires you to submit an application for a card and receive an approval or denial. The result of an application is mostly based on your credit score, although other factors are relevant to some banks. If you already have good credit, your score generally impacts your credit limits on cards as well as your likelihood of approval.

If you've never applied for credit before or you need to rebuild your credit after having some negative credit issues, getting the approval you need can be a little more challenging. Before you rack up a number of credit inquiries — which slightly reduce your credit score — by randomly applying for cards, take some time to learn which credit card issuers are most likely to approve your application. Start by checking out these tips on getting a credit card and using it wisely.

What Do Credit Card Companies Care About?

The main factor used in determining whether an applicant is approved for a credit card is the person's credit score. Before you apply, you can ask for a free copy of your credit report and your score from each of the three main credit reporting agencies: Experian, Equifax and TransUnion. According to the Fair Credit Reporting Act , you are entitled to a free copy of your report from each agency every 12 months. However, you can also get an estimate of your score at any time from other free or low-cost services, such as Credit Karma.

Photo Courtesy: 10'000 Hours/DigitalVision/Getty Images

A credit score below 580 is considered poor, 580-669 is considered fair, 670-739 is classified as good, 740 to 799 hits the level of very good and 800 to 850 is exceptional. On the low end of the spectrum, if your score is poor, it doesn't mean you won't qualify for a credit card. However, the cards you qualify for may have high yearly fees or high interest rates. Despite their shortcomings, these cards can be used to establish and build your credit when you don't have other better options available.

Beyond your credit score, the main thing a credit card company cares about is your ability to make monthly payments on the account. They will take your age and income into consideration when determining this. If you're younger than 21, you need to be able to prove that you have steady income and that you are able to afford the monthly payments on the card. If you're older than 21, you still have to meet certain requirements, but you may already have some type of payment history for credit card companies to review before making a decision about issuing credit to you.

One of the questions on the credit card application will ask for information about your yearly or monthly income. Most of the time, credit card companies won't fact check this information, but it's wise to be honest about your income, not just for the creditor's sake, but for your own. If you're already struggling to make ends meet, getting a new credit card could prompt you to spend money you can't afford to pay back, and that's never a good idea. You can always speak to a financial counselor for additional guidance prior to applying.

How to Choose a Credit Card

The higher your credit score, the better your chance of getting approved for credit. High scores allow you to be more selective about your choice of credit card. If your credit is in the good range or above, make sure you pay close attention to details and choose a card that doesn't have a high (or any) yearly fee and that has a competitive APR (annual percentage rate). For reference, a good APR today is generally below 17.57% , according to the Federal Reserve, but credit card rates tend to continuously increase over time.

Photo Courtesy: Boy_Anupong/Moment/Getty Images

Some credit card companies also offer rewards, such as cash back on purchases or rewards toward purchases — Amazon gift cards, for example — so this is something to take into consideration. Be aware that some credit card companies charge an annual fee, but plenty of banks do not. This is why it's incredibly important to read the fine print before filling out an application for a credit card. If the card you want comes with a high annual fee, it should offer some really exceptional benefits, such as free hotel upgrades or higher percentages of cash back.

Credit cards may have different APRs for different types of purchases. If you anticipate using your card to make cash advances, for instance, you want to check to make sure the card you're applying for has a reasonable APR for cash advances. The APRs for these types of special transactions can be much higher than 17.57%, even on good cards.

How Do I Apply for a Credit Card?

Most credit card applications are processed online, although you may have received a credit card application in the mail that you can physically fill out and return. Before starting the application, you want to make sure you have all the information on hand that you're likely to need. Most credit card companies will ask for information that is pretty straightforward. Be ready with your name, address, date of birth, maiden name, social security number, employment information and your monthly or yearly income.

Photo Courtesy: Eva_Katalin/E+/Getty Images

If you're applying online, fill out all the required fields and submit the information. In most cases, you will be notified immediately of the credit decision. If you're approved, your card will usually arrive in one to two weeks. If you're denied, you will receive a letter in the mail explaining the reasons for the negative decision. The letter may also include your credit score on record at the bureau used to retrieve your score.

In some cases, you may receive a message that the bank needs more information. This is more common with applicants who are applying for credit for the first time. If this happens, follow the instructions for completing the application process. For example, the company may ask for proof of income or proof of identity or both.

If you submitted an application by mail, you can expect to receive your card in about four to six weeks if you're approved. If you're denied, the letter with the explanation generally only takes a couple of weeks to arrive.

Using Your Credit Card Wisely

It's very important to use your credit card wisely once you receive it. Far too often, credit card users fall into poor spending patterns that cause their debt to mount quickly. Overusing credit cards can lead to getting stuck in a loop of making only minimum payments while the balance — and interest paid — continues to grow.

Photo Courtesy: Predrag Vuckovic/E+/Getty Images

Remember that even a "good" APR is quite high at typically more than 17%, so it's good money management to pay your balance in full each month or only keep a small balance on the card. Interest can accrue quickly when you don't pay your balance, and when your card approaches its credit limit, this negatively affects your credit rating. Missed payments and delinquent accounts also tremendously affect your credit score, putting you in danger of not being approved for loans, mortgages and other types of credit you might need.

Webiste To Mockup Playing Cards

Source: https://www.reference.com/business-finance/credit-card-8d02fc82ec1fd56?utm_content=params%3Ao%3D740005%26ad%3DdirN%26qo%3DserpIndex

Read More

Business Card Mockup Desk

Business Card Mockup Desk

Dear Friends! Here you can find our new collection of Free PSD Business Card MockUps that we have taken from the different popular web resources for you to save you time and money. They all are extremely good for many goals and ideas. Choose the best Free business card mockup for you and enjoy the results of your work.

MockUps are necessary for making a presentation of the designers work. It is one of the easiest and elegant ways to achieve the necessary objectives.

Business card is the element of the corporate identity of the company, which has become the most accustomed in the work and daily life. But when sorting through those business cards that have accumulated at any person, you can see that they are significantly different from each other. It is pleasant to hold for a long time a lot of cards because they are really worthy of your attention.

A lot of designers create many business card for different companies, businessmen, corporations, shops, saloons and other kinds of business. The last part of such a work is approval of the design with the customer. Very important detail is to make such a presentation for your client to understand your design and idea and agree with the proposed.

This set that we have collected for you is very multipurpose. There are a lot of minimal business card mockups and many of them are very bright and colorful. Anyone can find there the appropriate mockup and finish the presentation. Make the right choice and you are welcome to come back again!

---

LetterPress Business Card MockUp Free PSD

A photorealistic PSD business card mock-up to present your business card design with the unique, tactile feel of letterpress printing. Use the smart layers to place your design and change the business cards side color via adjustment layer.

Download

---

Free Gold Edge LetterPress Bcard Mock-Up PSD

Photorealistic business card with golden edges, letterpress effect and changeable reflection based on your artwork . Includes smart objects, easy to customize.

Download

---

Free Folder, Letterhead & Business Card Mockup Template

Download

---

Wooden Business Card MockUps Free PSD

Here's a PSD mock-up designed for those who love the natural look and feel of wooden business cards. Use the smart objects to showcase both sides of your business cards design. Further you can change the color of your design and the background color.

Download

---

Free PSD Business Card MockUps

Download

---

Business card and Macbook Mockup

Visit the website

---

8 Free clean Business Card MockUps

Download

---

PREMIUM Business Card MockUp

Visit the website

---

---

Free Business Cards Mockups PSD

Download

---

Free Falling Business Cards Mockups PSD

Download

---

PSD Business Card MockUp Free

A new simple and effective psd business card mockup to showcase your brand design in style. You can easily add your own graphics thanks to the smart layer.

Download

---

PSD Business Card MockUp Free

An original psd business card mockup to display your next branding project. Easily add your business card design using the smart layer.

Download

---

PREMIUM Flying Business Card MockUp

Visit the website

---

PSD Business Card MockUp Free

A new front and back psd business card mockup to showcase your branding designs with style. You can add your own graphics with ease thanks our smart layers.

Download

---

Gravity PSD Bcards Mockups Free

A subtle rounded corner gravity business card mockup. Easily add your own designs and present them with an original falling perspective.

Download

---

PSD Business Card MockUp Free

This is a subtle and elegant business card mockup to showcase your front and back designs. Easily add your graphics with our smart layers

Download

---

Business Card Hand MockUp Free PSD

Business Card Hand Mockup is a mock-up created to showcase your elegant card design in the best and realistic way, full layered and renamed is easy to use! With a few clicks you can customized to your needs, your design will be presented in a great realistic way.

Download

---

PREMIUM Business Card MockUp

Visit the website

---

Business Card MockUp Free PSD

Elegant multiple stacked of free business cards psd mockup to display your business card design with style, created specially for 3.5″x2.0″ size designs, very easy to use. Designed with smart objects that allow you to create elegant showcases of your projects

Download

---

Business Card MockUp Free PSD

This Business Card mockup helps you to promote your stylish card designs, is a PSD Mockup fully editable and you can change the color of what you want.

Download

---

A4 Letterhead and Business Cards MockUp Free PSD

This mockups is useful to show your Letterhead and Business Card Designs, highlighting the design of your business card on a letterhead, is really easy to use this mockup becomes a great resource to show your work to your clients, your design will be presented in a great realistic way.

Download

---

Business Cards MockUp Free PSD

This Free PSD Mockup help you to display your business card design in a great photo-realistic presentation, with a simple double click and drag and drop into the smart object, your design will be presented in a stunning way.

Download

---

PREMIUM Simple Black and White Business Card MockUp

Visit the website

---

Organica Business Card Tag and Product MockUp

This product mockup is extremely effective looking at the overall appearance containing 3 editable designs(Business Card ,Tag and Product).Overall, it is easy to see the whole package and its intended impact.

Download

---

Business Card MockUp Free PSD

To add your card designs, first hide the top yellow layer and double-click the smart object layer below it. Follow the layers in the .psb file to edit and add your cards and background. You can even change the reflective shadows to make it realistic.

Download

---

Business Card and Food Box Mockup

Visit the website

---

Tiled Perspective Business Card MockUp Freebie PSD

The PSD mockup include smart-objects that helps you to add your business card design and make them realistic tiled cards. Ideal to showcase your brand identity in a beautiful way!

Download

---

Business Card MockUp Freebie PSD

Download

---

PREMIUM Colorful Business Card MockUp

Visit the website

---

Free Business Card PSD MockUp

Download

---

Free Business Card PSD MockUp

Download

---

Special Event Business Card MockUp Free

Download

---

7+ Business Cards MockUPs Free PSD

You can use on your presentation project. This is excelent! Quick overlay mockup of standard dimensions 9 x 5 cm. Three on a white sheet, the other also on the desk with a laptop. If you like you can download and use freely.

Download

---

PREMIUM Business Card MockUp

Visit the website

---

6 Business Cards MockUPs Free PSD

Set of 6 totally free to mock up a more colorful presentation to the client.
Include a high resolution of 300 dpi, 2500 x 1875 px, with further layers intelligent smart filter blur.

Download

---

Free Simple Business Card Mockup PSD

Download

---

Customizable Free Business Card MockUp PSD

Free business card mockup to showcase your card designs in a subtle and elegant way. This high quality business card mockup features realistic shadows, editable card design, customizable background and floor color. Simply add your design via provided Smart Object Layers in the PSD file and your all ready to present your business card design.

Download

---

Free Standing Business Cards MockUps (3 PSD)

Download

---

Free PSD business card mockups with iPhone 6

Free PSD business card mockups with iPhone 6 mockup on wooden table in office. You can use more filters to stylize your picture and present your corporate identity better. Our "Mocups" are really easy to use because of using smart layers.

Download

---

PREMIUM Modern Business Card MockUp

Visit the website

---

Free PSD business card mockups on wooden table

Download

---

Photorealistic free PSD Mockup of the Business card

Download

---

Photorealistic PSD mockup business card

Download

---

4 Free Business Card MockUps PSD

Download

---

PREMIUM Business Card MockUp

Visit the website

---

Free Business Card 2 Stacks MockUp PSD

Download

---

Free PSD MockUP – Business Card

Download

---

Realistic Business Cards MockUp Free PSD

Create an elegant presentation for your business card designs with this original and photorealistic mock-up. The PSD file allows you to easily place your design on the cards via the smart objects, and to change the background to build the perfect scene.

Download

---

Free Architecture Business Card

Download

---

PREMIUM Business Card MockUp

Visit the website

---

Vintage Cameras and B-Cards MockUPs Free PSD

This mock-up includes two scenes featuring two stacks of business cards and two vintage cameras with a perspective and top views. You can apply your design via the smart objects and change the color of the business cards to create the right combination.

Download

---

Cutout Wood & Embossed B-Card MockUp

This realistic mock-up of a stack of embossed business cards and cutout wooden plaque is perfect to showcase an original and stylish branding identity project. The PSD file includes smart objects for a photorealistic effect and flawless result.

Download

---

Stack Letterpress Business Cards MockUp Freebie PSD

Add your design through the smart objects and change the background color to create a flawless presentation.

Download

---

Realistic Business Card MockUp Free PSD

A photorealistic stack business card mock-up that allows you to showcase your design in a simple yet stylish way. Add your design easily by placing it inside the smart object and you're done in no time. This great freebie was handcrafted by Javier Torres.

Download

---

MockUp Business Card Rounded edges Freebie

Download

---

PREMIUM Car Sales Business Card MockUp

Visit the website

---

Ultimte Business Card MockUps Free Download

Download

---

Business Card PSD MockUPs Free

Download

---

Flying Business Card – Free PSD MockUP

Download

---

Elegant Vintage MockUps Freebie PSD

Today's special is a set of photography based elegant vintage mock-ups including 3 styles: Golden letterpress, Regular and Vintage letterpress. Just paste in your own design into the Smart Object layer and see it appear on the mock-up! This freebie has been created byAmris. Be sure to check out her shop for more awesome mock-ups!

Download

---

PREMIUM Trinity Business Card MockUp

Visit the website

---

Free Simple Business Card Template

Download

---

Free Business Card MockUp

Freebie mock-up to present your logo or insignia design in a photo-realistic way. Ideally for white backgrounds designs. Editable via smart objects.

Download

---

Free Business Card MockUp PSD

A very photo realistic mock-up, just replace images with your designs using "Smart Objects", and enjoy the result!

Download

---

Folded Business Card PSD MockUP Free

Create a realistic Folded Business Card display in few seconds. These PSD files uses the Smart Object, You can replace the mockup content easily and quickly.

Download

---

Business Card PSD MockUP Free

Business Card PSD Mockup v4 is a realistic Business Card in Metal Box 100% PSD Mockup. Create a realistic Business Card display in few seconds. By using Smart Object, You can replace the mockup content easily and quickly.

Download

---

Business Card PSD MockUP Free

This is an other special Business Card PSD Mockup v2, show your Business Card templates with Professional style, Create a realistic Business Card display in few seconds. These PSD files uses the Smart Object, You can replace the mockup content easily and quickly.

Download

---

A collection of 6 Business card mock ups Free PSD

Download

---

Freebie Business Card MockUp PSD

Download

---

Free Square Business Card MockUp Free PSD

Download

---

Free PSD Business Card Display MockUP – Forest

Download

---

Free PSD Display MockUp vertical Business Card – HOOT

Download

---

Belisama – Free PSD Business Card Display MockUp

Download

---

Simple DJ Business Card Template

Download

---

Business Card MockUP Freebie

Download

---

Freebie Clean Business Card MockUP PSD

Download

---

Business Card MockUP PSD

This is a free psd business card mockup to let you display your next business card design. You can set the card border color and use our smart layer for an easy drag and drop action.

Download

---

Business Card Free MockUp PSD

Download

---

Stack Business Card MockUp Free

Download

---

Free PSD Business Card MockUP

This is the light themed psd business card mock-up template with its elegant cardboard box. (3,15×2 inch)

Download

---

Business Card MockUP Free

Download

---

Free square Business card MockUp PSD

Download

---

Free Business Card MockUP

Super easy to use Business Card Mockup. Present Your Business Card in a very simple and elegant way. Including depth of field, ligh effect. All you have to do is to "Edit content" and paste your design in smart objects. Help File included.

Download

---

Business Card MockUp Free PSD

Card is necessary to present yourself as a professional person in the market.
Today we've business card mockup for designers, Download card template and make your design more effective and beautiful, check detail page as reference.

Download

---

Free Vertical Business Cards PSD MockUp PSD

Download this beautiful Vertical Business Cards PSD Mockup, Easy to apply your designs using smart objects, just double click the Smart Layer, copy & paste your artwork, save and you're done! Download & Enjoy!

Download

---

Thank you for watching till the end! We hope you have found the best mockup for you and your business! Have great deals!

(3 votes, average: 4.3 out of 5)

Business Card Mockup Desk

Source: https://free-psd-templates.com/free-psd-business-card-mockups/

Read More